SIBSGENOMICS: Systematic Investigation of Blacks With Stroke - GENOMICS

Sponsor
University College Hospital, Ibadan (Other)
Overall Status
Recruiting
CT.gov ID
NCT05619406
Collaborator
Medical University of South Carolina (Other), University of Ibadan (Other), Federal Medical Centre, Abeokuta (Other), Ahmadu Bello University Teaching Hospital (Other), Bayero University Kano, Nigeria (Other), Kwame Nkrumah University of Science and Technology (Other), Korle-Bu Teaching Hospital, Accra, Ghana (Other), University of Alabama at Birmingham (Other), University of Washington (Other)
100
3
2
3.8
33.3
8.7

Study Details

Study Description

Brief Summary

The overall goal of SIBS-GENOMICS is to utilize the best available contextual data on stroke in Africa to develop & validate stroke risk estimation models, translate the best model into a mobile phone app and conduct a randomized control trial of the app with a co-created motivational education video, to determine their effectiveness for improvement of stroke risk factor awareness and global risk reduction among Africans.

Condition or Disease Intervention/Treatment Phase
  • Device: Riskometer Application
  • Behavioral: Routine Clinic Therapy
N/A

Detailed Description

Africa now bears a foremost burden of stroke worldwide with age standardized stroke incidence rate of up to 316 per 100,000, a prevalence of 1.46 per 1,000 population,1 month fatality of 40% & a 3-year mortality rate of 84%.

The burden of stroke on the continent falls heavily on the young productive age group & is associated with profound diminution in the quality of life via disability, depression, & vascular cognitive impairment.

World Health Organization estimates that stroke deaths in LMIC account for 86% of stroke deaths worldwide & disability-adjusted life years lost in LMIC is 7X those lost in high-income countries (HIC). Beyond the personal toll, costs related to stroke are prohibitive and threaten to erode the recent economic gains in Africa where the stroke is a major threat to brain health, brain capital and human capital. The surge in stroke burden in Africa is driven by an unprecedented rise in precursory modifiable cardiometabolic risk factors.

There is an urgent need to deploy evidence-based approaches using the best available context-specific data to surmount the stroke epidemic on the continent by developing population-wide preventive interventions. Achieving this goal requires tackling key barriers to stroke prevention such as lack of awareness and self-directed action to control its risk factors.

Systematic Investigation of Blacks With Stroke (SIBS-GENOMICS) is poised to utilize the best available context-specific data on stroke in Africa to improve, validate, and co-create the first ever Afrocentric stroke riskometer mobile phone application, a self-management tool for stroke prevention. The app, along with a tailored co-created stroke prevention motivational video and educational modules with customized behavioral change activities, will be evaluated for effectiveness to improve individual stroke risk factor awareness and control in the first-of-its-kind randomized control trial (RCT) for a digital tool for primary stroke prevention in Africa.

With the scarcity of acute care and rehabilitation services, coupled with the chronic economic burden imposed by stroke, prevention is evidently the best option towards reducing its burden in Africa. This is concordant with the core mission of the NINDS to reduce the burden of stroke in the USA and globally through translational research and innovation.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
100 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
The relational data model is adopted in the Model component of the systemThe relational data model is adopted in the Model component of the system
Masking:
Double (Investigator, Outcomes Assessor)
Masking Description:
The investigator and outcome assessor will be blinded
Primary Purpose:
Prevention
Official Title:
Systematic Investigation of Blacks With Stroke - GENOMICS (SIBS-GENOMICS)
Actual Study Start Date :
Aug 20, 2022
Actual Primary Completion Date :
Nov 6, 2022
Anticipated Study Completion Date :
Dec 15, 2022

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Control

The Control Group will be screened at baseline and be informed of their risk factors. They will be counselled to consult their provider following baseline risk factor assessment but this advice will not be reinforced by exposure to the app, stroke video, or module content. At the end of the study (EOS), they will complete a questionnaire to assess possible contamination with the intervention.

Device: Riskometer Application
The intervention group participants at baseline will be assessed by installing a riskometer app on their mobile phones to calculate their global stroke risk score. They will be shown their risk scores and the specific risk factors identified through the screening. They will be counselled and supported to manage their risk factors through lifestyle changes and visit their healthcare provider for appropriate care.

Experimental: Intervention

The riskometer app will be administered one-on-one to the participants using a smartphone and eventually score and assess them using the global risk score

Behavioral: Routine Clinic Therapy
After their assessment by the blinded adjudicator, the controls will visit the study doctor to obtain the routine clinic therapy and then will be allowed to go home.

Outcome Measures

Primary Outcome Measures

  1. Primary Outcome [2 months]

    Total stroke risk probability (0 to 100%) calculated by the software. Reduction in total score of at least 10% over 2 months

Secondary Outcome Measures

  1. Secondary Outcome [2 months]

    Stroke risk factors awareness score. List of risk factors will be based on SIREN findings and developed into a questionnaire which will be pretested and validated; and translated/back-translated. Change in individual risk factors will also be assessed and compared.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • male or female (sex is a biologic variable of interest).

  • age greater than or equal to 18 years.

  • with at least 2 stroke risk factors based on the list of 11 top most modifiable risk factors identified in the SIREN study (including hypertension, diabetes mellitus, dyslipidemia, smoking, overweight, physical inactivity, or unbalanced/poor diet).

  • ownership or access to smartphones in consenting stroke-free adults.

Exclusion Criteria:
  • prior history of vascular disease (e.g., stroke, transient ischemic attack, angina, myocardial infarction, peripheral vascular disease, and atrial fibrillation), or cognitive impairment; not comfortable reading and writing, depression or other psychiatric disorders (through personal declaration) likely to affect the interventions; participation in another RCT; other conditions rendering the individual unsuitable to participate in this research as judged by treating physicians.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Kwame Nkrumah University of Science and Technology (KNUST) Kumasi Ghana 00000
2 Ahmadu Bello University Teaching Hospital, (ABUTH) Zaria Zaria Kaduna Nigeria 810107
3 University College Hospital Ibadan Oyo Nigeria 20021

Sponsors and Collaborators

  • University College Hospital, Ibadan
  • Medical University of South Carolina
  • University of Ibadan
  • Federal Medical Centre, Abeokuta
  • Ahmadu Bello University Teaching Hospital
  • Bayero University Kano, Nigeria
  • Kwame Nkrumah University of Science and Technology
  • Korle-Bu Teaching Hospital, Accra, Ghana
  • University of Alabama at Birmingham
  • University of Washington

Investigators

  • Principal Investigator: Mayowa O. Owolabi, MD, College of Medicine, University of Ibadan
  • Principal Investigator: Bruce Ovbiagele, MD, University of California, San Francisco
  • Principal Investigator: Fred S. Sarfo, PhD, Kwame Nkrumah University of Science & Technology (KNUST)
  • Principal Investigator: Benjamin S. Aribisala, PhD, Lagos State University, (LASU)
  • Principal Investigator: Michelle Nichols, PhD, Medical University of South Carolina
  • Principal Investigator: Oyedunni S. Arulogun, PhD, University of Ibadan
  • Principal Investigator: Carolyn Jenkins, PhD, Medical University of South Carolina
  • Principal Investigator: Bukola Ajala, PhD, University of Ibadan
  • Principal Investigator: Onoja M. Akpa, PhD, University of Ibadan
  • Principal Investigator: Odun J. Akinyemi, PhD, University of Ibadan
  • Principal Investigator: Rufus A. Akinyemi, PhD, University of Ibadan
  • Principal Investigator: Reginald O. Obiako, PhD, Ahmadu Bello University Teaching Hospital, (ABUTH) Zaria

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
Mayowa Owolabi, Professor, University College Hospital, Ibadan
ClinicalTrials.gov Identifier:
NCT05619406
Other Study ID Numbers:
  • UI/EC/18/0706
First Posted:
Nov 16, 2022
Last Update Posted:
Nov 16, 2022
Last Verified:
Nov 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Mayowa Owolabi, Professor, University College Hospital, Ibadan
Additional relevant MeSH terms:

Study Results

No Results Posted as of Nov 16, 2022